|
Các ấn phẩm nghiên cứu ký sinh trùng sốt rét kháng thuốc, thuốc sốt rét giả và kém chất lượng
1.Alker, A.P., Lim, P., Sem, R., Shah, N.K., Yi, P., Bouth, D.M., Tsuyuoka, R., Maguire, J.D., Fandeur, T., Ariey, F., Wongsrichanalai, C., Meshnick, S.R (2007), “Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border”, Am. J. Trop. Med. Hyg. 76, 641–647. 2.Ambrose O Talisuna, Corine Karema, Bernhards Ogutu, Elizabeth Juma, John Logedi, Andrew Nyandigisi, Modest Mulenga, Wilfred F Mbacham, Cally Roper,Philippe J Guerin, Umberto D’Alessandro (2012), “Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems”, Lancet Infect Dis. 2012 November; 12(11): 888–896. 3.Amin AA, Kokwaro GO. (2007), “Antimalarial drug quality in Africa”, J Clin Pharm Ther. 2007 Oct;32(5):429-40. 4.Anderson, T.J., Nair, S., Nkhoma, S., Williams, J.T., Imwong, M., Yi, P., Socheat, D., Das, D., Chotivanich, K., Day, N.P., White, N.J., Dondorp, A.M. (2010), “High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia”, J. Infect. Dis. 2010, 1326–1330. 5.Ariey, F., Randrianarivelojosia, M., Duchemin, J.B., Rakotondramarina, D., Ouledi, A., Robert, V., Jambou, R., Jahevitra, M., Andrianantenaina, H., Raharimalala, L.,Mauclere, P., (2002), “Mapping of a Plasmodium falciparum pfcrt K76T mutation: a useful strategy for controlling chloroquine resistance in Madagascar”. J. Infect. Dis. 185, 710–712. 6.Ariey, F., Fandeur, T., Durand, R., Randrianarivelojosia, M., Jambou, R., Legrand, E., Ekala, M.T., Bouchier, C., Cojean, S., Duchemin, J.B., Robert, V., Le Bras, J., Mercereau-Puijalon, O., (2006),“Invasion of Africa by a single pfcrt allele of south east Asian type”, Malar. J. 5, 34. 7.Ashley EA, Krudsood S et al., (2004), “Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand”, J. Infect Dis. 2004 Nov 15;190(10):1773-82. 8.Ashley, E.A., Stepniewska, K., Lindegardh, N., Annerberg, A., Kham, A., Brockman, A., Singhasivanon, P., White, N.J., Nosten, F., (2007), “How much fat is necessary to optimize lumefantrine oral bioavailability?”, Trop. Med. Int. Health 12, 195–200. 9.Aung Pyae Phyo, Standwell Nkhoma, Kasia Stepniewska, Elizabeth A Ashley, Shalini Nair, Rose McGready, Carit ler Moo, Salma Al-Saai, Arjen M Dondorp, Khin Maung Lwin, Pratap Singhasivanon, Nicholas PJ Day, Nicholas J White, Tim JC Anderson, François Nosten (2012),“Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study”, Lancet, Vol.379, Issue 9830, pp.1960 – 1966. 10.Baird JK, Caneta-Miguel E et al., (2003), “Survey of resistance to chloroquine of falciparum and vivax malaria in Palawan, the Philippines”, Ann. Pharmacother, 2003 Apr; 37(4):526-9. 11.Baird JK, Hoffman LS et al., (2004), “Primaquine therapy for malaria, Clinical and Infectious diseases”, Clin Infect Dis. (2004) 39 (9): 1336-1345. 12.Baird JK et al., (2009), “Resistance to therapies for infection by Plasmodium vivax”, Clin Microbiol Rev, 2009 Jul; 22(3): 508-34 13.Barnardas C, Ratsimbasoa A, Tichit M, Bouchier C et al.,(2008), “Plasmodium vivax resistance to chloroquine in Madagasca: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes”. Antimicrob Agents Chemother, 2008 Dec; 52(12):4233-40. 14.Barnes, K.I., Watkins, W.M., White, N.J., (2008), “Antimalarial dosing regimens and drug resistance”, Trends parasitol. 24, 127–134. 15.Basco LK, Ringwald P (2001), “Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaounde, Cameroon”, J. Infect Dis 2001;183:1828-31. 16.Basco, L.K., (2003), “Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance in Plasmodium falciparum”, Am. J. Trop. Med. Hyg. 69, 174–178. 17.Breman, J.G., Alilio, M.S., Mills, A., (2004), “Conquering the intolerable burden of malaria: what’s new, what’s needed: a summary”, Am. J. Trop. Med. Hyg. 71, 1–15. 18.Bruno B A, Antonio R F, Sebastiao et al., (2010), “Severe Plasmodium vivax malaria exhibits marked inflamatory imbalance”, Malaria Journal 2010, 9:13. 19.Campino, S., Auburn, S., Kivinen, K., Zongo, I., Ouedraogo, J.B., Mangano, V., Djimde, A., Doumbo, O.K., Kiara, S.M., Nzila, A., Borrmann, S., Marsh, K., Michon, P., Mueller, I., Siba, P., Jiang, H., Su, X.Z., Amaratunga, C., Socheat, D., Fairhurst, R.M., Imwong, M., Anderson, T., Nosten, F., White, N.J., Gwilliam, R., Deloukas, P.,MacInnis, B., Newbold, C.I., Rockett, K., Clark, T.G., Kwiatkowski, D.P., (2011), “Population genetic analysis of Plasmodium falciparum parasites using a customized illumina goldengate genotyping assay”, PLoS one 6, e20251. 20.Carrara, V.I., Zwang, J., Ashley, E.A., Price, R.N., Stepniewska, K., Barends, M., Brockman, A., Anderson, T., McGready, R., Phaiphun, L., Proux, S., van Vugt, M., Hutagalung, R., Lwin, K.M., Phyo, A.P., Preechapornkul, P., Imwong, M., Pukrittayakamee, S., Singhasivanon, P., White, N.J., Nosten, F., (2009), “Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment”, PLoS one 4, e4551. 21.Carlton JM, Adams JH, Silva JC et al.,(2008), “Comparative genomics of the neglected human malaria parasite Plasmodium vivax”. Nature, 2008 Oct 9; 455(72):757-63. 22.Certain, L.K., Briceno, M., Kiara, S.M., Nzila, A.M., Watkins, W.M., Sibley, C.H., (2008), “Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987–2006”, J. Infect. Dis. 197, 1743–1751. 23.Cheeseman, I.H., Miller, B.A., Nair, S., Nkhoma, S., Tan, A., Tan, J.C., Al Saai, S., Phyo, A.P., Moo, C.L., Lwin, K.M., McGready, R., Ashley, E., Imwong, M., Stepniewska, K., Yi, P., Dondorp, A.M., Mayxay, M., Newton, P.N., White, N.J., Nosten, F., Ferdig, M.T., Anderson, T.J., (2012), “A major genome region underlying artemisinin resistance in malaria”, Science 336, 79–82. 24.Chen N et al. (2007), “Relapse of Plasmodium vivax infection result from clonal hypnozoites activated at predeterminated intervals”, Journal of infectious diseases, 195:934-941. 25.Christopher JL Murray, Lisa C Rosenfeld, Stephen S Lim, Kathryn G Andrews, Kyle J Foreman, Diana Haring, Nancy Fullman, Mohsen Naghavi, Rafael Lozano, Alan D Lopez (2012), “Global malaria mortality between 1980 and 2010: a systematic analysis”, The Lancet, Vol.379, Issue 9814:413 - 431, 26.Cisse B, Sokhna C, Boulanger D, et al (2006), “Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial”, Lancet; 367:659-667. 27.Cortese JF, Caraballo A et al (2002), “Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America”, J. Infect Dis; 186:999-1006. 28.Davis, R.G., Kamanga, A., Castillo-Salgado, C., Chime, N., Mharakurwa, S., Shiff, C., (2011), “Early detection of malaria foci for targeted interventions in endemic southern Zambia”, Malar. J. 10, 260. 29.Ding XC, Beck HP, Raso G (2011), “Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets”, Trends Parasitol. 2011 Feb;27(2):73-81. 30.Ding XC, Ubben D, Wells TN (2012), “A framework for assessing the risk of resistance for anti-malarials in development”, Malar J. 2012 Aug 22;11:292. 31.Djimde A, Doumbo OK, Cortese JF, et al., (2001), “A molecular marker for chloroquine-resistant falciparum malaria”, N. Engl J Med; 344:257-263. 32.Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM, Yeung S, Petit A, Lynam AJ, Johnson A, Hien TT, McGready R, Farrar JJ, Looareesuwan S, Day NP, Green MD, White NJ. (2004), “Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials”, Trop Med Int Health. 2004 Dec;9(12):1241-6. 33.Dondorp, A.M., Nosten, F., Yi, P., Das, D., Phyo, A.P., Tarning, J., Lwin, K.M., Ariey, F., Hanpithakpong, W., Lee, S.J., Ringwald, P., Silamut, K., Imwong, M., Chotivanich, K., Lim, P., Herdman, T., An, S.S., Yeung, S., Singhasivanon, P., Day, N.P.J., Lindegardh, N., Socheat, D., White, N.J., (2009), “Artemisinin resistance in Plasmodium falciparum malaria”, N. Engl. J. Med. 361, 455–467. 34.Dondorp, A.M., Yeung, S., White, L., Nguon, C., Day, N.P.J., Socheat, D., von Seidlein, L., (2010), “Artemisinin resistance. current status and scenarios for containment”, Nat. Rev. Microbiol. 8, 272–280. 35.Duffy, P.E., Mutabingwa, T.K., (2004), “Drug combinations for malaria: time to ACT?” Lancet 363, 3–4. 36.Dzinjalamala, F.K., Macheso, A., Kublin, J.G., Taylor, T.E., Barnes, K.I., Molyneux, M.E., Plowe, C.V., Smith, P.J., (2005), “Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine–pyrimethamine in Malawian children”, Antimicrob. Agents Chemother. 49, 3601–3606. Elyazar, I.R., Hay, S.I., Baird, J.K., (2011), “Malaria distribution, prevalence, drug resistance and control in Indonesia”, Adv. Parasitol. 74, 41–175. 37.Flegg, J.A., Guerin, P.J., White, N.J., Stepniewska, K., (2011), “Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator”, Malar. J. 10, 339. 38.Fryauff DJ, Tuti S, Mardi A et al.,(2004), “Chloroquine resistant Plasmodium vivax in transmigration settlement of West Kalimantan, Indonesia”, Am J Trop Med Hyg; 59 (4):513-8 39.Genton B at al.(2008), “Plasmodium vivax and mixed infection are associated with severe malaria in children: a prospective cohort study from Papua New Guinea”, Plos Medicine, 5:e127. 40.Gething, P.W., Patil, A.P., Smith, D.L., Guerra, C.A., Elyazar, I.R., Johnston, G.L., Tatem, A.J., Hay, S.I., (2011), “A new world malaria map: Plasmodium falciparum endemicity in 2010”, Malar. J. 10, 378. 41.Gething, P.W., Van Boeckel, T.P., Smith, D.L., Guerra, C.A., Patil, A.P., Snow, R.W., Hay, S.I., (2011), “Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax”, Parasitol. Vectors 4, 92. 42.Ghulam Rahim Awab, Sasithon Pukrittayakamee, Mallika Imwong, Arjen M Dondorp, Charles J Woodrow, Sue Jean Lee, Nicholas PJ Day, Pratap Singhasivanon, Nicholas J White, Faizullah Kaker (2010), “Dihydroartemisinin - piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial”, Malaria Journal 2010, 9:105. 43.Goller JL et al.(2007), “Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy”, American Journal of Tropical medicine & Hygiene, 76:203-207. 44.Gogtay NJ, Desai S, Kadam VS et al., (2000), “Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria”, J. Assoc Physicician India, 2000 Nov; 48(11):1085-6. 45.Guthmann JP, Pittet A, Lesage A et al., (2008), “Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar”, Trop Med. Int Health 2008, Jan, 13 (1): 91-8. 46.Hall KA, Newton PN, Green MD, De Veij M, Vandenabeele P, Pizzanelli D, Mayxay M, Dondorp A, Fernandez FM. (2006), “Characterization of counterfeit artesunate antimalarial tablets from southeast Asia”, Am J Trop Med Hyg. 2006 Nov;75(5):804-11. 47.Hanpithakpong, W., Kamanikom, B., Singhasivanon, P., White, N.J., Day, N.P., Lindegardh, N., (2009), “A liquid chromatographic–tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma”, Bioanalysis 1, 37–46. 48.Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, Gerena L, et al., (2003), “Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria”, Ann Trop Med Parasitol 2003; 97: 439-51. 49.Hastings, I., Watkins, W., (2006), ‘Tolerance is the key to understanding antimalarial drug resistance”, Trends in Parasitol. Volume 22, Issue 2, pp. 71–77. 50.Hastings I (2011), “How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance”, Trends in Parasitol. 2011;27(2):67-72. 51.Harald Noedl, Youry Se et al., (2009), “Evidence of Artemisinin-Resistant Malaria in Western Cambodia”, N. Engl J Med, 2008, Dec 11; 359 (24) 2619-20. 52.Hill DR et al. (2006), “Primaquine: report from CDC expert meeting on malaria chemoprophylaxis”, American Journal of Tropical medicine and Hygiene, 75:402-415. 53.Imwong M, Snounou G, Nurhayati et al., (2007), “Plasmodium vivax infection usually result from activation of heterologous hypnozoites”. Journal of Infectious Diseases, Apr 1, 195(7): 927-933. 54.Julien Zwang, Elizabeth A. Ashley, Corine Karema et al., (2009), “Safety and efficacy of Dihydroartemisinin - piperaquine in falciparum malaria: A prospective multi-centre individual patient data analysis”, PLoS one 4(7): e6358. 55.Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH, et al., (2009), “Pharmacogenetics of antimalarial drugs: effect on metabolism and transport”, Lancet Infect Dis 2009; 9: 760-74. 56.Kublin, J., Dzinjalamala, F., Kamwendo, D., Malkin, E., Cortese, J., Martino, L., Mukadam, R., Rogerson, S., Lescano, A., Molyneux, M., Winstanley, P., Chimpeni, P., Taylor, T., Plowe, C., (2002), “Molecular markers for failure of sulfadoxine–pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria”, J. Infect. Dis. 185, 380–388. 57.Laufer, M., Thesing, P., Eddington, N., Masonga, R., Dzinjalamala, F., Takala, S., Taylor, T., Plowe, C., (2006), “Return of chloroquine antimalarial efficacy in Malawi”, N. Engl. J. Med. 355, 1959–1966. 58.Laufer, M.K., Djimde, A.A., Plowe, C.V., (2007), “Monitoring and deterring drugresistant malaria in the era of combination therapy”, Am. J. Trop. Med. Hyg. 77, 160–169. 59.Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM (2002), “Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate”, J Pharmacol Exp Ther 2002; 300: 399-407. 60.Lim, P., Alker, A.P., Khim, N., Shah, N.K., Incardona, S., Doung, S., Yi, P., Bouth, D.M., Bouchier, C., Puijalon, O.M., Meshnick, S.R., Wongsrichanalai, C., Fandeur, T., Le Bras, J., Ringwald, P., Ariey, F., (2009), “Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia”, Malar. J. 12; 8:11. 61.Lim, P., Wongsrichanalai, C., Chim, P., Khim, N., KIM, S., Chy, S., Sem, R., Nhem, S., Yi, P., Duong, S., Bouth, D.M., Genton, B., Beck, H.-P., Gobert, J.G., Rogers, W.O., Coppee, J.-Y., Fandeur, T., Mercereau-Puijalon, O., Ringwald, P., Le Bras, J., Ariey, F., (2010), “Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine and quinine in Cambodia from 2001 to 2007”, Antimicrob. Agents Chemother., AAC.01304–01309. 62.Lindegardh, N., Annerberg, A., White, N.J., Day, N.P., (2008), “Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B: Analyt”, Technol. Biomed. Life Sci. 862, 227–236. 63.Lin JT, Juliano JJ, Wongsrichanalai C et al., (2010), “Drug-resistant malaria: the era of ACTs”. Curr Infect Dis Rep 2010; 12: 165-73. 64.Lon CT, Tsuyuoka R, Phanouvong S, Nivanna N, Socheat D, Sokhan C, Blum N, Christophel EM, Smine A (2006), “Counterfeit and substandard antimalarial drugs in Cambodia”, Trans R Soc Trop Med Hyg. 2006 Nov;100(11):1019-24. 65.Maguire JD, Susanti AI, Kristin , Sismadi P, Fryauff DJ, Baird JK. The T76 mutation in the pfcrt gene of Plasmodium falciparum and clinical chloroquine resistance phenotypes in Papua, Indonesia. Ann Trop Med Parasitol 2001; 95: 559-72. 66.Maiga, O., Djimde, A.A., Hubert, V., Renard, E., Aubouy, A., Kironde, F., Nsimba, B., Koram, K., Doumbo, O.K., Bras, J.L., Clain, J., (2007), “A shared asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa”,J. Infect. Dis. 196, 165–172. 67.Mehlotra RK, Henry-Halldin CN, Zimmerman PA (2009), “Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy”, Pharmacogenomics 2009; 10:435-49. 68.Mendez, F., Munoz, A., Carrasquilla, G., Jurado, D., Arevalo-Herrera, M., Cortese, J.F., Plowe, C.V., (2002), “Determinants of treatment response to sulfadoxine–pyrimethamine and subsequent transmission potential in falciparum malaria”, Am. J. Epidemiol. 156, 230–238. 69.Mendez, F., Herrera, S., Murrain, B., Gutierrez, A., Moreno, L., Manzano, M., Munoz, A., Plowe, C., (2007), “Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine–pyrimethamine treatment and infectivity to anopheles mosquitoes”, Am. J. Trop. Med. Hyg. 77, 438–443. 70.Menemedengue, V., Sahnouni, K., Basco, L., Tahar, R., (2011), “Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunatesulfadoxine–pyrimethamine combination”, Am. J. Trop. Med. Hyg. 85, 22–25. 71.Mint Lekweiry, K., Ould Mohamed Salem Boukhary, A., Gaillard, T., Wurtz, N., Bogreau, H., Hafid, J.E., Trape, J.-F., Bouchiba, H., Ould Ahmedou Salem, M.S.,Pradines, B., Rogier, C., Basco, L.K., Briolant, S., (2012), “Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in nouakchott, mauritania. J. Antimicrob. Chemother. 67, 367–374. 72.Mita T, Kaneko A, Lum JK et al (2006), “Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi”, Am J Trop Med Hyg; 68:413-415. 73.Mita, T., Venkatesan, M., Ohashi, J., Culleton, R., Takahashi, N., Tsukahara, T., Ndounga, M., Dysoley, L., Endo, H., Hombhanje, F., Ferreira, M.U., Plowe, C.V., Tanabe, K., (2011), “Limited geographic origin and global spread of sulfadoxineresistant dhps alleles in Plasmodium falciparum populations”, J. Infect. Dis. 204, 1980–1988. 74.Mohapatra MK, Padhiary KN, Mishra DP et al., (2002), “Atypical manifestations of Plasmodium vivax malaria”, Indian J Malariol, 2002; 39 (1-2):18-25 75.Mok, S., Imwong, M., Mackinnon, M.J., Sim, J., Ramadoss, R., Yi, P., Mayxay, M., Chotivanich, K., Liong, K.Y., Russell, B., Socheat, D., Newton, P.N., Day, N.P., White, N.J., Preiser, P.R., Nosten, F., Dondorp, A.M., Bozdech, Z., 2011. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12, 391. 76.Myint HY, Ashley EA, Day NP, Nosten F, White NJ et al., (2007), “Efficacy and safety of dihydroartemisinin-piperaquine”, Trans R Soc Trop Med Hyg. 2007 Sep;101(9):858-66. 77.Nayyar GM, Breman JG, Newton PN, Herrington J (2012), “Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa”, Lancet Infect Dis. 2012 Jun;12(6):488-96. 78.Nelson AL, Purfield A, McDaniel P, Uthaimongkol N, Buathong N, Sriwichai S et al., (2005), “pfmdr1 genotyping and in vivo mefloquine resistance on the Thai-Myanmar border”, Am J Trop Med Hyg; 72: 586-92. 79.Newton P, Proux S, Green M, Smithuis F, Rozendaal J, Prakongpan S, Chotivanich K, Mayxay M, Looareesuwan S, Farrar J, Nosten F, White NJ (2001), “Fake artesunate in southeast Asi”, Lancet. 2001 Jun 16;357(9272):1948-50. 80.Newton PN et al., (2009), “Counterfeit and substandard anti-infectives in developing countries in antimicrobial resistance in developing countries”, Springer; 2009:413-443. 81.Newton PN, Green MD, Mildenhall DC, Plançon A, Nettey H, Nyadong L, Hostetler DM, Swamidoss I, Harris GA, Powell K, Timmermans AE, Amin AA, Opuni SK, Barbereau S, Faurant C, Soong RC, Faure K, Thevanayagam J, Fernandes P, Kaur H, Angus B, Stepniewska K, Guerin PJ, Fernández FM (2011), “Poor quality vital anti-malarials in Africa - an urgent neglected public health priority”, Malar J. 2011 Dec 13;10:352 82.Nkhoma, S., Molyneux, M., Ward, S., (2007), “Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi”, Acta Trop. 102, 138–142. 83.Noedl, H., Se, Y., Schaecher, K., Smith, B.L., Socheat, D., Fukuda, M.M., (2008), “Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359, 2619–2620. 84.Noedl H, Socheat D, Satimai W (2009), “Artemisinin-resistant malaria in Asia”, N Engl J Med 2009; 361: 540-1. 85.Noranate, N., Durand, R., Tall, A., Marrama, L., Spiegel, A., Sokhna, C., Pradines, B., Cojean, S., Guillotte, M., Bischoff, E., Ekala, M., Bouchier, C., Fandeur, T., Ariey, F., Patarapotikul, J., LeBras, J., Trape, J., Rogier, C., Mercereau-Puijalon, O., 2007. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS one 2, e139. 86.Nosten, F., van Vugt, M., Price, R., Luxemburger, C., Thway, K.L., Brockman, A., McGready, R., ter Kuile, F., Looareesuwan, S., White, N.J., 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356, 297–302. 87.Ochong EO, van den Broek IV, Keus K, Nzila A (2003), “Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan”, Am J Trop Med Hyg 2003; 69: 184-7. 88.Omar SA, Adagu IS, Warhurst DC (2001), “Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure?”, Trans R Soc Trop Med Hyg 2001; 95: 315-9. 89.Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, et al., (2008), “Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers”, Eur J Clin Pharmacol 2008;64:683-90. 90.Pascal Ringwald, Amy Barrette, Charlotte Rasmussen, Robert D Newman (2012), “The global challenge of antimalarial drug resistance”, Malaria Journal 2012, 11(Suppl 1): O37 91.Pearce, R.J., Pota, H., Evehe, M.S., Ba el, H., Mombo-Ngoma, G., Malisa, A.L., Ord, R., Inojosa, W., Matondo, A., Diallo, D.A., Mbacham, W., van den Broek, I.V., Swarthout, T.D., Getachew, A., Dejene, S., Grobusch, M.P., Njie, F., Dunyo, S., Kweku, M., Owusu-Agyei, S., Chandramohan, D., Bonnet, M., Guthmann, J.P., Clarke, S., Barnes, K.I., Streat, E., Katokele, S.T., Uusiku, P., Agboghoroma, C.O., Elegba, O.Y., Cisse, B., IE, A.E., Giha, H.A., Kachur, S.P., Lynch, C., Rwakimari, J.B., Chanda, P., Hawela, M., Sharp, B., Naidoo, I., Roper, C., (2009), “Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria”, PLoS Med. 6, e1000055. 92.Picot, S., Olliaro, P., de Monbrison, F., Bienvenu, A., Price, R., Ringwald, P., (2009), “A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria”, Malar. J. 8, 89. 93.Pillai DR, Labbe AC, Vanisaveth V, Hongvangthong B, Pomphida S, Inkathone S, et al., (2001), “Plasmodium falciparum malaria in Laos: chloroquine treatment outcome and predictive value of molecular markers”, J Infect Dis 2001; 183: 789-95. 94.Plowe, C., (2005), “Antimalarial drug resistance in Africa: strategies for monitoring and deterrence”, Curr. Top. Microbiol. Immunol. 295, 55–79. 95.Plowe, C.V., (2003), “Monitoring antimalarial drug resistance. making the most of the tools at hand”, J. Exp. Biol. 206, 3745–3752. 96.Plowe, C.V., (2009), “The evolution of drug-resistant malaria”, Trans. R. Soc. Trop. Med. Hyg. 103 (Suppl. 1), S11–S14. 97.Price, R.N., Nosten, F., (2001), “Drug resistant falciparum malaria: clinical consequences and strategies for prevention”, Drug Resist. Updat. 4, 187–196. 98.Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al., (2004), “Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number”, Lancet 2004; 364:438-47. 99.H.H Quang, T.N Trung, Li Guoqiao, H.B. Phuoc (2008). Assessment of ACTs (Artemisinine based Combination Therapy) regimes drugs efficacy for the treatment of uncomplicated falciparum malaria in some hyperendemic area, Central and west-highland area, Vietnam (2000-2008). International seminar of malaria management in Shanghai, China, July, 2008. 100.Roederer MW (2009), “Cytochrome P450 enzymes and genotype-guided drug therapy”, Curr Opin Mol Ther 2009; 11: 632-40. 101.Rogers, W.O., Sem, R., Tero, T., Chim, P., Lim, P., Muth, S., Socheat, D., Ariey, F., Wongsrichanalai, C., (2009), “Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia”, Malar. J. 8, 10. 102.Roper, C., Pearce, R., Bredenkamp, B., Gumede, J., Drakeley, C., Mosha, F., Chandramohan, D., Sharp, B., (2003), “Antifolate antimalarial resistance in southeast Africa: a population-based analysis”, Lancet 361, 1174–1181. 103.Roper, C., Pearce, R., Nair, S., Sharp, B., Nosten, F., Anderson, T., (2004), “Intercontinental spread of pyrimethamine-resistant malaria”, Science 305, 1124-. 104.Sanz LM, Crespo B, De-Cózar C, Ding XC, Llergo JL, Burrows JN, García-Bustos JF, Gamo FJ (2012), “P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action”, PLoS one. 2012;7(2):e30949. 105.Sibley, C.H., Barnes, K.I., Watkins, W.M., Plowe, C.V., (2008), “A network to monitor antimalarial drug resistance. a plan for moving forward”, Trends Parasitol. 24, 43–48. 106.Sibley, C.H., Hyde, J.E., Sims, P.F.G., Plowe, C.V., Kublin, J.G., Mberu, E.K., Cowman, A.F., Winstanley, P.A., Watkins, W.M., Nzila, A.M., (2001). Pyrimethamine– sulfadoxine resistance in Plasmodium falciparum: what next?” Trends Parasitol. 17, 570–571. 107.Sibley, C.H., Guerin, P.J., Ringwald, P., (2010), “Monitoring antimalarial resistance. launching a cooperative effort”, Trends Parasitol. 26, 221–224. 108.Smith, D., Klein, E., McKenzie, F.E., Laxminarayan, R., (2010), “Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty”, Malar. J. 9, 217. 109.Tatem, A.J., Smith, D.L., (2010), “International population movements and regional Plasmodium falciparum malaria elimination strategies”, Proc. Natl. Acad. Sci. USA 107, 12222–12227. 110.N.X. Thanh, T.N. Trung, N.C. Phong, H.H. Quang, B. Dai, George D. Shanks, Marina Chavchich, Michael D. Edstein (2012), “The efficacy and tolerability of artemisinin-piperaquine (Artequick(R)) versus artesunate-amodiaquine (CoarsucamTM) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam”, Malaria Journal 2012, 11:217. 111.N.X. Thanh, T.N. Trung, N.C. Phong, H.H. Quang, B. Dai, George D. Shanks, Marina Chavchich, Michael D. Edstein (2012), “Efficacy of artesunate alone and Artesunate plus Azithromycin for the treatment of uncomplicated Plasmodium falciparum malaria in Vietnam”, Abstract for the 61st Annual meeting of the American Society of Tropical Medicine and Hygiene, November 11-15, Atlanta, USA. 112.T.N Trung, T.M.E Davis, S. Hewitt, L.K Thuan, H.H Quang et al., (2001). Treatment of falciparum malaria in Vietnamese children: the need for combination therapy and optimized dosage regimens. Annals of Tropical Paediatrics: International Child Health, Vol. 21, No. 4:307-312. 113.Wang X, Mu J, Li G et al., (2005), “Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan”, People's Republic of China, Am J Trop Med Hyg;72:410-414. 114.White, N.J., (2004), “Antimalarial drug resistance”, J. Clin. Invest. 113, 1084–1092. 115.White, N.J., Stepniewska, K., Barnes, K., Price, R.N., Simpson, J., (2008), “Simplified antimalarial therapeutic monitoring: using the day-7 drug level?”, Trends Parasitol. 24, 159–163. 116.White NJ (2008), “Qinghaosu (artemisinin): the price of success”, Science 2008; 320: 330-4. 117.White NJ et al., (2009), “Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance”, Malar J 2009, 8:253. 118.White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP (2009), “Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance”, Malar J.2009 Nov 11;8:253. 119.White, N.J., (2010), “Artemisinin resistance–the clock is ticking”, Lancet 376, 2051–2052. 120.WHO (2006), The threat of resistance to artemisinine derivatives, WHO briefing on malaria treatment guidelines and artemisinine monotherapies, Geneva,2006. pp.13-17. 121.WHO (2006), Uncomplicated Plasmodium vivax treatment, WHO Guidelines for the treament of malaria, pp. 187-201. 122.WHO (2007), WHO/GMP_Standardized data entry for therapeutic efficacy tests. http://www.who.int/malaria/resistance. 123.WHO (2008), Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. http://www.who.int/malaria 124.WHO (2008), Global malaria control and elimination: report of a meeting on containment of artemisinine tolerance. Geneva, WHO, http://www.who.int/malaria/resistance. 125.WHO (2009), Artemisinin resistance in Plasmodium falciparum malaria, http://www.who.int/malaria/resistance. 126.WHO (2009), In vivo and in vitro Excelsheet form_Data entry, version 7.1. 127.WHO (2009), Drug resistance could set back malaria control success, New release, http://www.who.int/malaria/resistance 128.WHO (2009), Methods for surveillance of antimalarial drug efficacy. http://www.who.int/malaria/resistance. 129.WHO (2009), Parasitological confirmation of malaria diagnosis. Report of a WHO technical consultation Geneva, 6-8 Oct 2009 130.WHO (2009), Report of the workshop to review and plan therapeutic efficacy studies to monitor P. falciparum and P. vivax resistance to antimalarial drugs in the Greater Mekong Sub-region, Mandalay, Myanmar, 2009. http://www.who.int/malaria/resistance. 131.WHO (2010), Guidelines for the treatment of malaria, Second edition. http://www.who.int/malaria. 132.WHO (2010), Global report antimalarial drugs efficacy and drugs resistance 2000-2010, http://www.who.int/malaria 133.WHO (2010), Global malaria programme: Q and A antimalarial drug efficacy and drug resistance. http://www.who.int/malaria/resistance. 134.WHO (2011), Global Plan for Artemisinin Resistance Containment. WHO, Geneva. 135.WHO (2011). Methods and technique for assessing exposure to antimalarial drugs in clinical field studies. Informal consultation organized by the World health organisation with the technical supports of the world wide antimalarial resistance network (WWARN). 136.WHO (2011). Universal assess to malaria diagnostic testing. An operational manual 2011. 137.WHO (2012), WHO Global malaria programme. World malaria report 2012. 138.WHO (2012), The status of drug-resistant malaria along the Thailand-Myanmar border. http://www.who.int/ malaria/ revised 09 May 2012 139.WHO (2012), WHO urges action as drug-resistant malaria spreads. http://www.who.int/malaria/resistance 140.Yeka A, et al. (2008), “Artemether-Lumefantrine versus DHA+PPQ for treating uncomplicated malaria: A randomized trial to guide policy in Uganda”, PLoS onE 3(6): e2390. 141.Zwang Julien, Ashley Elizabeth A, Karema Corine et al., (2009), “Safety and efficacy of DHA+PPQ in falciparum malaria: a prospective multi-centre individual patient data analysis”, PloS one 2009;4(7):e6358).
|
TRANG CHỦ
